LEADER 01752nam  2200517   450 
001 9910796464303321
005 20230803215038.0
010   $a0-309-36840-5
035   $a(CKB)3810000000019665
035   $a(EBL)3379436
035   $a(SSID)ssj0001535816
035   $a(PQKBManifestationID)11862579
035   $a(PQKBTitleCode)TC0001535816
035   $a(PQKBWorkID)11508075
035   $a(PQKB)10372645
035   $a(MiAaPQ)EBC3379436
035   $a(Au-PeEL)EBL3379436
035   $a(CaPaEBR)ebr11042784
035   $a(OCoLC)923291273
035   $a(EXLCZ)993810000000019665
100   $a20150425h20142014  uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aCharacterizing uncertainty in the assessment of benefits and risks of pharmaceutical products $eworkshop in brief /$fInstitute of Medicine (U.S.)
210  1$a[Washington, District of Columbia] :$cInstitute of Medicine of the National Academies,$d2014.
210  4$dİ2014
215   $a1 online resource (8 p.)
225 1 $aWorkshop in Brief
300   $aDescription based upon print version of record.
327   $a""Characterizing Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products-Workshop in Brief""
410  0$aWorkshop in brief.
606   $aRisk assessment$vCongresses
606   $aCommunication$vCongresses
615  0$aRisk assessment
615  0$aCommunication
676   $a363.1
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910796464303321
996   $aCharacterizing uncertainty in the assessment of benefits and risks of pharmaceutical products$93846851
997   $aUNINA